Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market US$ 3.5 Billion by 2021

MARYLAND HEIGHTS, Mo. - Sept. 29, 2017 - PRLog -- The global idiopathic pulmonary fibrosis treatment market research report provides market size (Revenue USD Million 2014 to 2021), patient numbers by disease severity and by country (U.S., Japan, U.K. Germany, France, Italy, Spain, 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global idiopathic pulmonary fibrosis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global idiopathic pulmonary fibrosis treatment market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.

The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments. Major players operating in the global idiopathic pulmonary fibrosis treatment market and profiled in this report include Aeolus Pharmaceuticals, Baxter International, Biogen, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Gilead Sciences, Inventiva Pharma, MediciNova, Inc., Merck & Co. (Afferent Pharmaceuticals, Inc.), Promedior, Inc., Prometheus Laboratories, Inc., and Shionogi & Company.

Visit Idiopathic Pulmonary Fibrosis (IPF) Treatment Market by Treatment Type - Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity (Mild, Moderate, Severe); Drug Pipeline Analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050) and Forecast 2017-2021 https://www.ihealthcareanalyst.com/report/idiopathic-pulm...

1.Treatment Type

1.1.Pharmacological Treatment - Drug (Brand)

1.1.1.Pirfenidone (Esbriet)

1.1.2.Nintedanib (Ofev)

1.1.3.Generic Pirfenidone

1.2.Non-pharmacological Treatment

1.2.1.Oxygen Therapy

1.2.2.Pulmonary Rehabilitation

1.2.3.Mechanical Ventilation

1.2.4.Lung Transplantation

1.2.5.Other Non-Pharmacological Treatment

2.Patients (Disease Severity)

2.1.Mild

2.2.Moderate

2.3.Severe

3.Pipeline Analysis

3.1.AEOL-10150

3.2.Lebrikizumab

3.3.Tipelukast

3.4.Tralokinumab

3.5.FG-3019

3.6.Simtuzumab

3.7.BMS-986020

3.8.AF-219

3.9.SAR156597

3.10.BG00011

3.11.PRM-151

3.12.PBI-4050

4.Geography

4.1.North America (U.S., Canada)

4.2.Latin America (Brazil, Mexico, Rest of LA)

4.3.Europe (U.K., Germany, France, Italy, Spain, Rest of EU)

4.4.Asia Pacific (Japan, China, India, Rest of APAC

4.5.Rest of the World

5.Company Profiles

5.1.Aeolus Pharmaceuticals

5.2.Baxter International

5.3.Biogen, Inc.

5.4.Boehringer Ingelheim

5.5.F. Hoffmann-La Roche

5.6.FibroGen, Inc.

5.7.Gilead Sciences

5.8.Inventiva Pharma

5.9.MediciNova, Inc.

5.10.Merck & Co. (Afferent Pharmaceuticals, Inc.)

5.11.Promedior, Inc.

5.12.Prometheus Laboratories, Inc.

5.13.Shionogi & Company

To request Table of Contents and Sample Pages of this report visit:

https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/

About Us

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client's specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us

iHealthcareAnalyst, Inc.

2109, Mckelvey Hill Drive,

Maryland Heights, MO 63043

United States

Email: sales@ihealthcareanalyst.com

Website: https://www.ihealthcareanalyst.com